Nanoscope Therapeutics Inc. announced four presentations on the Company’s preclinical and clinical research in retinitis pigmentosa and Stargardt macular degeneration at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting, being held May 1 – 4, 2022, in Denver, Colorado.
DALLAS , April 26, 2022 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic therapies for treatment of retinal degenerative diseases, today announced four presentations on the Company’s preclinical and clinical research in retinitis pigmentosa (RP) and Stargardt macular degeneration at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting, being held May 1 – 4, 2022, in Denver, Colorado.
“We are excited to showcase the breadth and depth of our gene therapy programs from creating disease models to mutation-agnostic gene therapy, and novel instrumentation for assessing retinal function and functional vision in pre-clinical models and in the clinic,” said Sulagna Bhattacharya, CEO of Nanoscope “Our presentations highlight our efforts to address outer retinal degenerative diseases with the goal of bringing relief to the millions of patients worldwide.”
Nanoscope presentations at ARVO-2022:
AAV-carried MCO Optogenetic Therapy for the Treatment of Inherited Retinal Disorders
Presenter: Subrata Batabyal, Ph.D.
Date/Time: May 1, 2022; 12:15 PM - 2:15 PM MDT
Location: A0047, Poster Hall
Presenter: Samarendra Mohanty, Ph.D.
Date/Time: May 2, 2022; 12:30 PM - 2:30 PM MDT
Location: F0040, Poster Hall
Establishing a novel preclinical laser-induced model for regenerative therapies of the outer retina
Presenter: Silvia Aparicio Domingo, MS.
Date/Time: May 2, 2022; 1:00 PM - 3:00 PM MDT
Location: F0399, Poster Hall
Presenter: Sanghoon Kim, Ph.D.
Date/Time: May 4, 2022; 11:08 AM - 11:25 PM MDT
Location: 4EF, Mile High Ballroom
About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing optogenetic therapies to give sight to millions of patients suffering from retinal degenerative diseases. Nanoscope’s lead product, MCO-010, is an investigational AAV gene therapy designed to restore functional vision to patients with severe vision loss due to retinal degeneration. In a Phase 1/2a open label trial of MCO-010 in patients with advanced RP (n=11), MCO-010 demonstrated a favorable safety profile and several patients experienced restoration of vision to a level sufficient to resume activities of daily living. A multicenter, randomized, double-masked, sham-controlled Phase 2b clinical trial of MCO-010 for treatment of RP (NCT04945772) is fully enrolled (N=27) and in follow-up. Primary data are expected in H1-2023. The company will begin Phase-2 clinical trials for Stargardt macular degeneration in Q2-2022. MCO therapy received orphan drug designations from the FDA for RP and Stargardt.
Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716
View original content to download multimedia:https://www.prnewswire.com/news-releases/nanoscopes-vision-restoring-optogenetic-gene-therapy-to-be-featured-in-multiple-presentations-as-part-of-arvo-annual-meeting-in-denver-may-1-4-2022-301532711.html
SOURCE Nanoscope Therapeutics
